Kintara Therapeutics, Inc. - FORM 8-K - EX-99.1 - DELMAR PHARMACEUTICALS, INC. EXHIBIT 99.1 - November 25, 2014

Attached files

file filename
8-K - DELMAR PHARMACEUTICALS, INC. 8-K - Kintara Therapeutics, Inc.f8k112514_delmar.htm

Exhibit 99.1

 

DelMar Pharmaceuticals, Inc.            
         
October 31, 2014 Pro Forma Balance Sheet            
(Unaudited)      Pro Forma Adjustments 
                          October
                                31, 2014
    September                            Pro
    30, 2014
Balances		    1    2    3    4    5   Forma Balances
Assets                              
                               
Current Assets                              
Cash and cash equivalents   4,315,746    738,626         -360,000             4,694,372
Taxes and other receivables   19,340                            19,340
Prepaid expenses   162,246                            162,246
    4,497,332    738,626    0    -360,000    0    0   4,875,958
                                 
Liabilities                                 
                               
Current liabilities                                 
Accounts payable and accrued liabilities  293,989                           293,989
Related party payables   41,674                            41,674
    335,663    0    0    0    0    0   335,663
                               
Stock option liability   182,065                            182,065
Derivative liability   3,458,662    -346,018    -825,502         916        2,288,058
    3,976,390    -346,018    -825,502    0    916    0   2,805,786
                                  
Stockholder's equity                                 
                                  
Preferred stock   278,530                            278,530
Common stock   36,842    1,136                   187   38,165
Additional paid-in capital   13,982,362    1,083,508    825,502              206,299   16,097,671
Warrants   6,187,805                            6,187,805
Accumulated deficit   -19,985,775              -360,000    -916    -206,486   -20,553,177
Accumulated other comprehensive income   21,178                            21,178
    520,942    1,084,644    825,502    -360,000    -916    0   2,070,172
                               
    4,497,332    738,626    0    -360,000    0    0   4,875,958

 

                         
Pro Froma Adjustments        
                         
1. To record proceeds of $738,626 from the exercise of 1,136,347 warrants at $0.65 per warrant and to record the reclassification of the pro rata portion of the related derivative liability to equity.
2. To record the reclassification of the Dividend Warrant portion of the derivative liability to equity upon the amendment of all of the Dividend Warrants.
3. To recognize the October 2014 expenses.
4. To recognize the change in the fair value of the remaining unexercised Investor Warrants from September 30, 2014 to October 31, 2014.
5. To recognize share-based payments related to shares and stock options issued for services during October 2014.

Kintara Therapeutics, Inc. Reports